{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T20:50:23Z","timestamp":1794948623790,"version":"4.9.1"},"reference-count":136,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T00:00:00Z","timestamp":1696291200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1038\/s41584-023-01032-1","type":"journal-article","created":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T10:02:55Z","timestamp":1696327375000},"page":"713-723","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Back to the future: targeting the extracellular matrix to treat systemic sclerosis"],"prefix":"10.1038","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2832-283X","authenticated-orcid":false,"given":"Andrew","family":"Leask","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angha","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Stratton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,3]]},"reference":[{"key":"1032_CR1","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41584-022-00765-9","volume":"18","author":"AL Herrick","year":"2022","unstructured":"Herrick, A. L., Assassi, S. & Denton, C. P. Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need. Nat. Rev. Rheumatol. 18, 276\u2013285 (2022).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1032_CR2","doi-asserted-by":"publisher","first-page":"102602","DOI":"10.1016\/j.autrev.2020.102602","volume":"19","author":"Y Jiang","year":"2020","unstructured":"Jiang, Y., Turk, M. A. & Pope, J. E. Factors associated with pulmonary arterial hypertension (PAH) in systemic sclerosis (SSc). Autoimmun. Rev. 19, 102602 (2020).","journal-title":"Autoimmun. Rev."},{"key":"1032_CR3","doi-asserted-by":"publisher","first-page":"4430","DOI":"10.3390\/ijms21124430","volume":"21","author":"U Attanasio","year":"2020","unstructured":"Attanasio, U. et al. Pulmonary hypertension phenotypes in systemic sclerosis: the right diagnosis for the right treatment. Int. J. Mol. Sci. 21, 4430 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"1032_CR4","doi-asserted-by":"publisher","first-page":"3686","DOI":"10.1093\/rheumatology\/keac006","volume":"61","author":"VS Siqueira","year":"2022","unstructured":"Siqueira, V. S. et al. Predictors of progression to systemic sclerosis: analysis of very early diagnosis of systemic sclerosis in a large single-centre cohort. Rheumatology 61, 3686\u20133692 (2022).","journal-title":"Rheumatology"},{"key":"1032_CR5","doi-asserted-by":"publisher","first-page":"4662","DOI":"10.1093\/rheumatology\/keab075","volume":"60","author":"RT Domsic","year":"2021","unstructured":"Domsic, R. T. et al. Defining the optimal disease duration of early diffuse systemic sclerosis for clinical trial design. Rheumatology 60, 4662\u20134670 (2021).","journal-title":"Rheumatology"},{"key":"1032_CR6","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/art.1780370218","volume":"37","author":"H Higley","year":"1994","unstructured":"Higley, H. et al. Immunocytochemical localization and serologic detection of transforming growth factor \u03b21. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud\u2019s phenomenon. Arthritis Rheum. 37, 278\u2013288 (1994).","journal-title":"Arthritis Rheum."},{"key":"1032_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/BOR.0000000000000898","volume":"34","author":"PS Tsou","year":"2022","unstructured":"Tsou, P. S., Shi, B. & Varga, J. Role of cellular senescence in the pathogenesis of systemic sclerosis. Curr. Opin. Rheumatol. 34, 343\u2013350 (2022).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1032_CR8","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/BOR.0000000000000835","volume":"33","author":"A Lescoat","year":"2021","unstructured":"Lescoat, A., Lecureur, V. & Varga, J. Contribution of monocytes and macrophages to the pathogenesis of systemic sclerosis: recent insights and therapeutic implications. Curr. Opin. Rheumatol. 33, 463\u2013470 (2021).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1032_CR9","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1038\/s41584-021-00683-2","volume":"17","author":"PS Tsou","year":"2021","unstructured":"Tsou, P. S., Varga, J. & O\u2019Reilly, S. Advances in epigenetics in systemic sclerosis: molecular mechanisms and therapeutic potential. Nat. Rev. Rheumatol. 17, 596\u2013607 (2021).","journal-title":"Nat. Rev. Rheumatol."},{"key":"1032_CR10","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1097\/BOR.0000000000000904","volume":"34","author":"S Shah","year":"2022","unstructured":"Shah, S. & Denton, C. P. Scleroderma autoantibodies in guiding monitoring and treatment decisions. Curr. Opin. Rheumatol. 34, 302\u2013310 (2022).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1032_CR11","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/13543784.2021.1923693","volume":"30","author":"A Lescoat","year":"2021","unstructured":"Lescoat, A., Varga, J., Matucci-Cerinic, M. & Khanna, D. New promising drugs for the treatment of systemic sclerosis: pathogenic considerations, enhanced classifications, and personalized medicine. Expert. Opin. Investig. Drugs 30, 635\u2013652 (2021).","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"1032_CR12","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","volume":"380","author":"O Distler","year":"2019","unstructured":"Distler, O. et al. Nintedanib for systemic sclerosis-associated interstitial lung disease. N. Engl. J. Med. 380, 2518\u20132528 (2019).","journal-title":"N. Engl. J. Med."},{"key":"1032_CR13","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/0049-0172(82)90055-5","volume":"11","author":"DC Haynes","year":"1982","unstructured":"Haynes, D. C. & Gershwin, M. E. The immunopathology of progressive systemic sclerosis (PSS). Semin. Arthritis Rheum. 11, 331\u2013351 (1982).","journal-title":"Semin. Arthritis Rheum."},{"key":"1032_CR14","first-page":"585","volume":"137","author":"AP Sappino","year":"1990","unstructured":"Sappino, A. P., Masouy\u00e9, I., Saurat, J. H. & Gabbiani, G. Smooth muscle differentiation in scleroderma fibroblastic cells. Am. J. Pathol. 137, 585\u2013591 (1990).","journal-title":"Am. J. Pathol."},{"key":"1032_CR15","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1074\/jbc.270.7.3423","volume":"270","author":"TZ Kirk","year":"1995","unstructured":"Kirk, T. Z., Mark, M. E., Chua, C. C., Chua, B. H. & Mayes, M. D. Myofibroblasts from scleroderma skin synthesize elevated levels of collagen and tissue inhibitor of metalloproteinase (TIMP-1) with two forms of TIMP-1. J. Biol. Chem. 270, 3423\u20133428 (1995).","journal-title":"J. Biol. Chem."},{"key":"1032_CR16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1749-6632.1985.tb51184.x","volume":"460","author":"T Krieg","year":"1985","unstructured":"Krieg, T., Perlish, J. S., Mauch, C. & Fleischmajer, R. Collagen synthesis by scleroderma fibroblasts. Ann. N. Y. Acad. Sci. 460, 375\u2013386 (1985).","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"1032_CR17","first-page":"S135","volume":"7","author":"EC LeRoy","year":"1989","unstructured":"LeRoy, E. C. The pathogenesis of systemic sclerosis. Clin. Exp. Rheumatol. 7, S135\u2013S137 (1989).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1032_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0889-857X(21)01042-5","volume":"16","author":"C Mauch","year":"1990","unstructured":"Mauch, C. & Kreig, T. Fibroblast-matrix interactions and their role in the pathogenesis of fibrosis. Rheum. Dis. Clin. North. Am. 16, 93\u2013107 (1990).","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"1032_CR19","doi-asserted-by":"publisher","first-page":"40967","DOI":"10.1074\/jbc.M307380200","volume":"278","author":"AJ van der Slot","year":"2003","unstructured":"van der Slot, A. J. et al. Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J. Biol. Chem. 278, 40967\u201340972 (2003).","journal-title":"J. Biol. Chem."},{"key":"1032_CR20","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/1523-1747.ep12364810","volume":"101","author":"M Ivarsson","year":"1993","unstructured":"Ivarsson, M., McWhirter, A., Black, C. M. & Rubin, K. Impaired regulation of collagen pro-\u03b11(I) mRNA and change in pattern of collagen-binding integrins on scleroderma fibroblasts. J. Invest. Dermatol. 101, 216\u2013221 (1993).","journal-title":"J. Invest. Dermatol."},{"key":"1032_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/0009-8981(94)90255-0","volume":"231","author":"G Bou-Gharios","year":"1994","unstructured":"Bou-Gharios, G., Osman, J., Black, C. & Olsen, I. Excess matrix accumulation in scleroderma is caused partly by differential regulation of stromelysin and TIMP-1 synthesis. Clin. Chim. Acta 231, 69\u201378 (1994).","journal-title":"Clin. Chim. Acta"},{"key":"1032_CR22","doi-asserted-by":"publisher","first-page":"194","DOI":"10.4103\/injr.injr_41_17","volume":"12","author":"A Wakhlu","year":"2017","unstructured":"Wakhlu, A. et al. Assessment of extent of skin involvement in scleroderma using shear wave elastography. Indian. J. Rheumatol. 12, 194\u2013198 (2017).","journal-title":"Indian. J. Rheumatol."},{"key":"1032_CR23","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/rheumatology\/ken370","volume":"47","author":"N Aden","year":"2008","unstructured":"Aden, N. et al. Proteomic analysis of scleroderma lesional skin reveals activated wound healing phenotype of epidermal cell layer. Rheumatology 47, 1754\u20131760 (2008).","journal-title":"Rheumatology"},{"key":"1032_CR24","first-page":"68","volume":"30","author":"Y Allanore","year":"2003","unstructured":"Allanore, Y. et al. Correlation of serum collagen I carboxyterminal telopeptide concentrations with cutaneous and pulmonary involvement in systemic sclerosis. J. Rheumatol. 30, 68\u201373 (2003).","journal-title":"J. Rheumatol."},{"key":"1032_CR25","doi-asserted-by":"publisher","first-page":"101191","DOI":"10.1016\/j.mam.2023.101191","volume":"92","author":"I Lurje","year":"2023","unstructured":"Lurje, I., Gaisa, N. T., Weiskirchen, R. & Tacke, F. Mechanisms of organ fibrosis: emerging concepts and implications for novel treatment strategies. Mol. Asp. Med. 92, 101191 (2023).","journal-title":"Mol. Asp. Med."},{"key":"1032_CR26","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/cei.13238","volume":"195","author":"M Brown","year":"2019","unstructured":"Brown, M. & O\u2019Reilly, S. The immunopathogenesis of fibrosis in systemic sclerosis. Clin. Exp. Immunol. 195, 310\u2013321 (2019).","journal-title":"Clin. Exp. Immunol."},{"key":"1032_CR27","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/BOR.0b013e32834b0dac","volume":"23","author":"L van Bon","year":"2011","unstructured":"van Bon, L., Cossu, M. & Radstake, T. R. An update on an immune system that goes awry in systemic sclerosis. Curr. Opin. Rheumatol. 23, 505\u2013510 (2011).","journal-title":"Curr. Opin. Rheumatol."},{"key":"1032_CR28","doi-asserted-by":"publisher","first-page":"885609","DOI":"10.3389\/fimmu.2022.885609","volume":"13","author":"L Wei","year":"2022","unstructured":"Wei, L., Abraham, D. & Ong, V. The Yin and Yang of IL-17 in systemic sclerosis. Front. Immunol. 13, 885609 (2022).","journal-title":"Front. Immunol."},{"key":"1032_CR29","doi-asserted-by":"publisher","first-page":"102526","DOI":"10.1016\/j.jaut.2020.102526","volume":"113","author":"JC Worrell","year":"2020","unstructured":"Worrell, J. C. & O\u2019Reilly, S. Bi-directional communication: conversations between fibroblasts and immune cells in systemic sclerosis. J. Autoimmun. 113, 102526 (2020).","journal-title":"J. Autoimmun."},{"key":"1032_CR30","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.jid.2016.11.037","volume":"137","author":"G Li","year":"2017","unstructured":"Li, G. et al. Skin-resident effector memory CD8+CD28\u2212 T cells exhibit a profibrotic phenotype in patients with systemic sclerosis. J. Invest. Dermatol. 137, 1042\u20131050 (2017).","journal-title":"J. Invest. Dermatol."},{"key":"1032_CR31","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1093\/rheumatology\/keaa195","volume":"59","author":"B Yaseen","year":"2020","unstructured":"Yaseen, B. et al. Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma. Rheumatology 59, 2625\u20132636 (2020).","journal-title":"Rheumatology"},{"key":"1032_CR32","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/1523-1747.ep12331160","volume":"107","author":"HA Makhluf","year":"1996","unstructured":"Makhluf, H. A. et al. IL-4 upregulates tenascin synthesis in scleroderma and healthy skin fibroblasts. J. Invest. Dermatol. 107, 856\u2013859 (1996).","journal-title":"J. Invest. Dermatol."},{"key":"1032_CR33","doi-asserted-by":"publisher","first-page":"eaas9944","DOI":"10.1126\/sciadv.aas9944","volume":"4","author":"T Matsushita","year":"2018","unstructured":"Matsushita, T. et al. BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance. Sci. Adv. 4, eaas9944 (2018).","journal-title":"Sci. Adv."},{"key":"1032_CR34","doi-asserted-by":"publisher","first-page":"R168","DOI":"10.1186\/ar4352","volume":"15","author":"A Fran\u00e7ois","year":"2013","unstructured":"Fran\u00e7ois, A. et al. B lymphocytes and B-cell activating factor promote collagen and profibrotic markers expression by dermal fibroblasts in systemic sclerosis. Arthritis Res. Ther. 15, R168 (2013).","journal-title":"Arthritis Res. Ther."},{"key":"1032_CR35","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1002\/art.21526","volume":"54","author":"T Matsushita","year":"2006","unstructured":"Matsushita, T. et al. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 54, 192\u2013201 (2006).","journal-title":"Arthritis Rheum."},{"key":"1032_CR36","doi-asserted-by":"publisher","first-page":"102444","DOI":"10.1016\/j.jaut.2020.102444","volume":"111","author":"M van der Kroef","year":"2020","unstructured":"van der Kroef, M. et al. CXCL4 triggers monocytes and macrophages to produce PDGF-BB, culminating in fibroblast activation: implications for systemic sclerosis. J. Autoimmun. 111, 102444 (2020).","journal-title":"J. Autoimmun."},{"key":"1032_CR37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0033508","volume":"7","author":"N Binai","year":"2012","unstructured":"Binai, N., O\u2019Reilly, S., Griffiths, B., van Laar, J. M. & H\u00fcgle, T. Differentiation potential of CD14+ monocytes into myofibroblasts in patients with systemic sclerosis. PLoS ONE 7, e33508 (2012).","journal-title":"PLoS ONE"},{"key":"1032_CR38","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1136\/annrheumdis-2016-210503","volume":"76","author":"AL Herrick","year":"2017","unstructured":"Herrick, A. L. et al. Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Ann. Rheum. Dis. 76, 1207\u20131218 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"1032_CR39","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1002\/acr.23282","volume":"70","author":"R Namas","year":"2018","unstructured":"Namas, R. et al. Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials. Arthritis Care Res. 70, 439\u2013444 (2018).","journal-title":"Arthritis Care Res."},{"key":"1032_CR40","doi-asserted-by":"publisher","first-page":"jcs227900","DOI":"10.1242\/jcs.227900","volume":"133","author":"P Pakshir","year":"2020","unstructured":"Pakshir, P. et al. The myofibroblast at a glance. J. Cell Sci. 133, jcs227900 (2020).","journal-title":"J. Cell Sci."},{"key":"1032_CR41","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1002\/art.23595","volume":"58","author":"S Liu","year":"2008","unstructured":"Liu, S. et al. Role of Rac1 in a bleomycin-induced scleroderma model using fibroblast-specific Rac1-knockout mice. Arthritis Rheum. 58, 2189\u20132195 (2008).","journal-title":"Arthritis Rheum."},{"key":"1032_CR42","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/art.30074","volume":"63","author":"S Liu","year":"2011","unstructured":"Liu, S., Shi-wen, X., Abraham, D. J. & Leask, A. CCN2 is required for bleomycin-induced skin fibrosis in mice. Arthritis Rheum. 63, 239\u2013246 (2011).","journal-title":"Arthritis Rheum."},{"key":"1032_CR43","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.ajpath.2019.09.006","volume":"190","author":"M Tsang","year":"2020","unstructured":"Tsang, M. et al. Insights into fibroblast plasticity: cellular communication network 2 is required for activation of cancer-associated fibroblasts in a murine model of melanoma. Am. J. Pathol. 190, 206\u2013221 (2020).","journal-title":"Am. J. Pathol."},{"key":"1032_CR44","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/S0002-9440(10)61252-7","volume":"167","author":"Y Chen","year":"2005","unstructured":"Chen, Y. et al. Matrix contraction by dermal fibroblasts requires transforming growth factor-\u03b2\/activin-linked kinase 5, heparan sulfate-containing proteoglycans, and MEK\/ERK: insights into pathological scarring in chronic fibrotic disease. Am. J. Pathol. 167, 1699\u20131711 (2005).","journal-title":"Am. J. Pathol."},{"key":"1032_CR45","doi-asserted-by":"publisher","first-page":"R1113","DOI":"10.1186\/ar1790","volume":"7","author":"VS Rajkumar","year":"2005","unstructured":"Rajkumar, V. S. et al. Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis. Arthritis Res. Ther. 7, R1113\u2013R1123 (2005).","journal-title":"Arthritis Res. Ther."},{"key":"1032_CR46","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1002\/1529-0131(199905)42:5<930::AID-ANR11>3.0.CO;2-1","volume":"42","author":"VS Rajkumar","year":"1999","unstructured":"Rajkumar, V. S., Sundberg, C., Abraham, D. J., Rubin, K. & Black, C. M. Activation of microvascular pericytes in autoimmune Raynaud\u2019s phenomenon and systemic sclerosis. Arthritis Rheum. 42, 930\u2013941 (1999).","journal-title":"Arthritis Rheum."},{"key":"1032_CR47","first-page":"846","volume":"60","author":"SA Young-Min","year":"2001","unstructured":"Young-Min, S. A. et al. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud\u2019s phenomenon, and in normal controls. Ann. Rheum. Dis. 60, 846\u2013851 (2001).","journal-title":"Ann. Rheum. Dis."},{"key":"1032_CR48","doi-asserted-by":"publisher","first-page":"S360","DOI":"10.1097\/00005344-199800001-00101","volume":"31","author":"S Xu","year":"1998","unstructured":"Xu, S. et al. Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J. Cardiovasc. Pharmacol. 31, S360\u2013S363 (1998).","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"1032_CR49","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1111\/j.1365-2133.1995.tb02743.x","volume":"133","author":"M Chanoki","year":"1995","unstructured":"Chanoki, M. et al. Increased expression of lysyl oxidase in skin with scleroderma. Br. J. Dermatol. 133, 710\u2013715 (1995).","journal-title":"Br. J. Dermatol."},{"key":"1032_CR50","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/art.38277","volume":"66","author":"D Rimar","year":"2014","unstructured":"Rimar, D. et al. Brief report: lysyl oxidase is a potential biomarker of fibrosis in systemic sclerosis. Arthritis Rheumatol. 66, 726\u2013730 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"1032_CR51","doi-asserted-by":"publisher","first-page":"L29","DOI":"10.1152\/ajplung.00173.2020","volume":"320","author":"XX Nguyen","year":"2021","unstructured":"Nguyen, X. X. et al. Lysyl oxidase directly contributes to extracellular matrix production and fibrosis in systemic sclerosis. Am. J. Physiol. Lung Cell Mol. Physiol. 320, L29\u2013L40 (2021).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"1032_CR52","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1021\/bi00825a004","volume":"9","author":"RC Siegel","year":"1970","unstructured":"Siegel, R. C., Pinnell, S. R. & Martin, G. R. Cross-linking of collagen and elastin. Properties of lysyl oxidase. Biochemistry 9, 4486\u20134492 (1970).","journal-title":"Biochemistry"},{"key":"1032_CR53","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/1523-1747.ep12274596","volume":"84","author":"L Peltonen","year":"1985","unstructured":"Peltonen, L., Palotie, A., Myllyl\u00e4, R., Krieg, T. & Oikarinen, A. Collagen biosynthesis in systemic scleroderma: regulation of posttranslational modifications and synthesis of procollagen in cultured fibroblasts. J. Invest. Dermatol. 84, 14\u201318 (1985).","journal-title":"J. Invest. Dermatol."},{"key":"1032_CR54","first-page":"1195","volume":"19","author":"Y Kawaguchi","year":"1992","unstructured":"Kawaguchi, Y. et al. Cytokine regulation of prolyl 4-hydroxylase production in skin fibroblast cultures from patients with systemic sclerosis: contribution to collagen synthesis and fibrosis. J. Rheumatol. 19, 1195\u20131201 (1992).","journal-title":"J. Rheumatol."},{"key":"1032_CR55","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/nrm809","volume":"3","author":"JJ Tomasek","year":"2002","unstructured":"Tomasek, J. J., Gabbiani, G., Hinz, B., Chaponnier, C. & Brown, R. A. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat. Rev. Mol. Cell Biol. 3, 349\u2013363 (2002).","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"1032_CR56","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1089\/wound.2012.0393","volume":"2","author":"L Van De Water","year":"2013","unstructured":"Van De Water, L., Varney, S. & Tomasek, J. J. Mechanoregulation of the myofibroblast in wound contraction, scarring, and fibrosis: opportunities for new therapeutic intervention. Adv. Wound Care 2, 122\u2013141 (2013).","journal-title":"Adv. Wound Care"},{"key":"1032_CR57","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/jcmm.12060","volume":"17","author":"R Ogawa","year":"2013","unstructured":"Ogawa, R. & Hsu, C. K. Mechanobiological dysregulation of the epidermis and dermis in skin disorders and in degeneration. J. Cell Mol. Med. 17, 817\u2013822 (2013).","journal-title":"J. Cell Mol. Med."},{"key":"1032_CR58","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1111\/wrr.12889","volume":"29","author":"A Leask","year":"2021","unstructured":"Leask, A. The hard problem: mechanotransduction perpetuates the myofibroblast phenotype in scleroderma fibrosis. Wound Repair. Regen. 29, 582\u2013587 (2021).","journal-title":"Wound Repair. Regen."},{"key":"1032_CR59","doi-asserted-by":"publisher","first-page":"124","DOI":"10.55563\/clinexprheumatol\/i80zh7","volume":"239","author":"R Spiera","year":"2021","unstructured":"Spiera, R. et al. A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. Clin. Exp. Rheumatol. 239, 124\u2013133 (2021).","journal-title":"Clin. Exp. Rheumatol."},{"key":"1032_CR60","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/S2213-2600(20)30318-0","volume":"8","author":"D Khanna","year":"2020","unstructured":"Khanna, D. et al. Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir. Med. 8, 963\u2013974 (2020).","journal-title":"Lancet Respir. Med."},{"key":"1032_CR61","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.3899\/jrheum.151322","volume":"43","author":"D Khanna","year":"2016","unstructured":"Khanna, D. et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS trial. J. Rheumatol. 43, 1672\u20131679 (2016).","journal-title":"J. Rheumatol."},{"key":"1032_CR62","first-page":"115","volume":"1","author":"A Leask","year":"2009","unstructured":"Leask, A. Signaling in fibrosis: targeting the TGFbeta, endothelin-1 and CCN2 axis in scleroderma. Front. Biosci. 1, 115\u2013122 (2009).","journal-title":"Front. Biosci."},{"key":"1032_CR63","doi-asserted-by":"publisher","first-page":"13008","DOI":"10.1074\/jbc.M210366200","volume":"278","author":"A Leask","year":"2003","unstructured":"Leask, A., Holmes, A., Black, C. M. & Abraham, D. J. Connective tissue growth factor gene regulation. Requirements for its induction by transforming growth factor-\u03b22 in fibroblasts. J. Biol. Chem. 278, 13008\u201313015 (2003).","journal-title":"J. Biol. Chem."},{"key":"1032_CR64","doi-asserted-by":"publisher","first-page":"12384","DOI":"10.1074\/jbc.M208544200","volume":"278","author":"VJ Thannickal","year":"2003","unstructured":"Thannickal, V. J. et al. Myofibroblast differentiation by transforming growth factor-\u03b21 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J. Biol. Chem. 278, 12384\u201312389 (2003).","journal-title":"J. Biol. Chem."},{"key":"1032_CR65","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1002\/art.24223","volume":"60","author":"X Shi-wen","year":"2009","unstructured":"Shi-wen, X. et al. Requirement of transforming growth factor \u03b2-activated kinase 1 for transforming growth factor \u03b2-induced \u03b1-smooth muscle actin expression and extracellular matrix contraction in fibroblasts. Arthritis Rheum. 60, 234\u2013241 (2009).","journal-title":"Arthritis Rheum."},{"key":"1032_CR66","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1002\/art.33482","volume":"64","author":"D Lagares","year":"2012","unstructured":"Lagares, D. et al. Inhibition of focal adhesion kinase prevents experimental lung fibrosis and myofibroblast formation. Arthritis Rheum. 64, 1653\u20131664 (2012).","journal-title":"Arthritis Rheum."},{"key":"1032_CR67","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1093\/rheumatology\/kes234","volume":"51","author":"X Shi-wen","year":"2012","unstructured":"Shi-wen, X. et al. Focal adhesion kinase and reactive oxygen species contribute to the persistent fibrotic phenotype of lesional scleroderma fibroblasts. Rheumatology 51, 2146\u20132154 (2012).","journal-title":"Rheumatology"},{"key":"1032_CR68","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s00441-016-2474-y","volume":"365","author":"Z Khan","year":"2016","unstructured":"Khan, Z. & Marshall, J. F. The role of integrins in TGF\u03b2 activation in the tumour stroma. Cell Tissue Res. 365, 657\u2013673 (2016).","journal-title":"Cell Tissue Res."},{"key":"1032_CR69","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1038\/sj.jid.5700331","volume":"126","author":"Y Asano","year":"2006","unstructured":"Asano, Y., Ihn, H., Jinnin, M., Mimura, Y. & Tamaki, K. Involvement of \u03b1v\u03b25 integrin in the establishment of autocrine TGF-\u03b2 signaling in dermal fibroblasts derived from localized scleroderma. J. Invest. Dermatol. 126, 1761\u20131769 (2006).","journal-title":"J. Invest. Dermatol."},{"key":"1032_CR70","doi-asserted-by":"publisher","first-page":"7708","DOI":"10.4049\/jimmunol.175.11.7708","volume":"175","author":"Y Asano","year":"2005","unstructured":"Asano, Y. et al. Increased expression of integrin \u03b1v\u03b23 contributes to the establishment of autocrine TGF-\u03b2 signaling in scleroderma fibroblasts. J. Immunol. 175, 7708\u20137718 (2005).","journal-title":"J. Immunol."},{"key":"1032_CR71","doi-asserted-by":"publisher","first-page":"499","DOI":"10.2353\/ajpath.2006.041306","volume":"168","author":"Y Asano","year":"2006","unstructured":"Asano, Y., Ihn, H., Yamane, K., Jinnin, M. & Tamaki, K. Increased expression of integrin \u03b1v\u03b25 induces the myofibroblastic differentiation of dermal fibroblasts. Am. J. Pathol. 168, 499\u2013510 (2006).","journal-title":"Am. J. Pathol."},{"key":"1032_CR72","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0092-8674(00)80545-0","volume":"96","author":"JS Munger","year":"1999","unstructured":"Munger, J. S. et al. The integrin \u03b1v\u03b26 binds and activates latent TGF \u03b21: a mechanism for regulating pulmonary inflammation and fibrosis. Cell 96, 319\u2013328 (1999).","journal-title":"Cell"},{"key":"1032_CR73","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1242\/jcs.070672","volume":"123","author":"S Liu","year":"2010","unstructured":"Liu, S. et al. Expression of integrin \u03b21 by fibroblasts is required for tissue repair in vivo. J. Cell Sci. 123, 3674\u20133682 (2010).","journal-title":"J. Cell Sci."},{"key":"1032_CR74","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1080\/07853890801986594","volume":"40","author":"J Myllyharju","year":"2008","unstructured":"Myllyharju, J. Prolyl 4-hydroxylases, key enzymes in the synthesis of collagens and regulation of the response to hypoxia, and their roles as treatment targets. Ann. Med. 40, 402\u2013417 (2008).","journal-title":"Ann. Med."},{"key":"1032_CR75","doi-asserted-by":"publisher","first-page":"106","DOI":"10.3109\/10409231003627991","volume":"45","author":"KL Gorres","year":"2010","unstructured":"Gorres, K. L. & Raines, R. T. Prolyl 4-hydroxylase. Crit. Rev. Biochem. Mol. Biol. 45, 106\u2013124 (2010).","journal-title":"Crit. Rev. Biochem. Mol. Biol."},{"key":"1032_CR76","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/S1357-2725(96)00121-5","volume":"29","author":"TJ Franklin","year":"1997","unstructured":"Franklin, T. J. Therapeutic approaches to organ fibrosis. Int. J. Biochem. Cell Biol. 29, 79\u201389 (1997).","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"1032_CR77","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/0168-8278(91)90006-W","volume":"13","author":"K B\u00f6ker","year":"1991","unstructured":"B\u00f6ker, K., Schwarting, G., Kaule, G., G\u00fcnzler, V. & Schmidt, E. Fibrosis of the liver in rats induced by bile duct ligation. Effects of inhibition by prolyl 4-hydroxylase. J. Hepatol. 13, S35\u2013S40 (1991).","journal-title":"J. Hepatol."},{"key":"1032_CR78","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1002\/hep.510280217","volume":"28","author":"M Bickel","year":"1998","unstructured":"Bickel, M. et al. Selective inhibition of hepatic collagen accumulation in experimental liver fibrosis in rats by a new prolyl 4-hydroxylase inhibitor. Hepatology 28, 404\u2013411 (1998).","journal-title":"Hepatology"},{"key":"1032_CR79","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1161\/hc4301.097193","volume":"104","author":"JI Nwogu","year":"2001","unstructured":"Nwogu, J. I. et al. Inhibition of collagen synthesis with prolyl 4-hydroxylase inhibitor improves left ventricular function and alters the pattern of left ventricular dilatation after myocardial infarction. Circulation 104, 2216\u20132221 (2001).","journal-title":"Circulation"},{"key":"1032_CR80","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/0041-008X(84)90066-8","volume":"73","author":"DM Bolarin","year":"1984","unstructured":"Bolarin, D. M., Palicharla, P. & Fuller, G. C. Enzymes of collagen synthesis in lung tissues of bleomycin-induced pulmonary fibrosis. Toxicol. Appl. Pharmacol. 73, 188\u2013191 (1984).","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"1032_CR81","doi-asserted-by":"publisher","first-page":"884","DOI":"10.7164\/antibiotics.31.884","volume":"31","author":"K Takeda","year":"1978","unstructured":"Takeda, K., Kawai, S., Kato, F., Tetsuka, T. & Konno, K. Stimulation of prolyl hydroxylase activity by bleomycin. J. Antibiot. 31, 884\u2013887 (1978).","journal-title":"J. Antibiot."},{"key":"1032_CR82","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1042\/bj2480625","volume":"248","author":"G Tschank","year":"1987","unstructured":"Tschank, G., Raghunath, M., G\u00fcnzler, V. & Hanauske-Abel, H. M. Pyridinedicarboxylates, the first mechanism-derived inhibitors for prolyl 4-hydroxylase, selectively suppress cellular hydroxyprolyl biosynthesis. Decrease in interstitial collagen and Clq secretion in cell culture. Biochem. J. 248, 625\u2013633 (1987).","journal-title":"Biochem. J."},{"key":"1032_CR83","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1021\/acschembio.5b00749","volume":"11","author":"JD Vasta","year":"2016","unstructured":"Vasta, J. D. et al. Selective inhibition of collagen prolyl 4-hydroxylase in human cells. ACS Chem. Biol. 11, 193\u2013199 (2016).","journal-title":"ACS Chem. Biol."},{"key":"1032_CR84","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.patbio.2004.12.033","volume":"53","author":"KM Szauter","year":"2005","unstructured":"Szauter, K. M., Cao, T., Boyd, C. D. & Csiszar, K. Lysyl oxidase in development, aging and pathologies of the skin. Pathol. Biol. 53, 448\u2013456 (2005).","journal-title":"Pathol. Biol."},{"key":"1032_CR85","unstructured":"Pharmaxis. Product pipeline: amine oxidase platform. Pharmaxis https:\/\/www.pharmaxis.com.au\/product-pipeline\/amine-oxidase-platform\/ (2023)."},{"key":"1032_CR86","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1200\/JCO.2011.38.9346","volume":"30","author":"JR Infante","year":"2012","unstructured":"Infante, J. R. et al. Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J. Clin. Oncol. 30, 1527\u20131533 (2012).","journal-title":"J. Clin. Oncol."},{"key":"1032_CR87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0218178","volume":"14","author":"A Peidl","year":"2019","unstructured":"Peidl, A., Perbal, B. & Leask, A. Yin\/Yang expression of CCN family members: transforming growth factor beta 1, via ALK5\/FAK\/MEK, induces CCN1 and CCN2, yet suppresses CCN3, expression in human dermal fibroblasts. PLoS ONE 14, e0218178 (2019).","journal-title":"PLoS ONE"},{"key":"1032_CR88","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1007\/s10637-015-0282-y","volume":"33","author":"SF Jones","year":"2015","unstructured":"Jones, S. F. et al. A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. Invest. N. Drugs 33, 1100\u20131107 (2015).","journal-title":"Invest. N. Drugs"},{"key":"1032_CR89","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.lungcan.2019.10.033","volume":"139","author":"DE Gerber","year":"2020","unstructured":"Gerber, D. E. et al. Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer. Lung Cancer 139, 60\u201367 (2020).","journal-title":"Lung Cancer"},{"key":"1032_CR90","doi-asserted-by":"publisher","first-page":"5254","DOI":"10.1158\/1078-0432.CCR-22-0308","volume":"28","author":"A Wang-Gillam","year":"2022","unstructured":"Wang-Gillam, A. et al. Defactinib, pembrolizumab, and gemcitabine in patients with advanced treatment refractory pancreatic cancer: a phase I dose escalation and expansion study. Clin. Cancer Res. 28, 5254\u20135262 (2022).","journal-title":"Clin. Cancer Res."},{"key":"1032_CR91","doi-asserted-by":"publisher","first-page":"djv123","DOI":"10.1093\/jnci\/djv123","volume":"107","author":"RA Fran\u00e7ois","year":"2015","unstructured":"Fran\u00e7ois, R. A. et al. Targeting focal adhesion kinase and resistance to mTOR inhibition in pancreatic neuroendocrine tumors. J. Natl Cancer Inst. 107, djv123 (2015).","journal-title":"J. Natl Cancer Inst."},{"key":"1032_CR92","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1038\/nm.3282","volume":"19","author":"NC Henderson","year":"2013","unstructured":"Henderson, N. C. et al. Targeting of \u03b1v integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat. Med. 19, 1617\u20131624 (2013).","journal-title":"Nat. Med."},{"key":"1032_CR93","doi-asserted-by":"publisher","first-page":"288ra79","DOI":"10.1126\/scitranslmed.aaa5094","volume":"7","author":"NI Reed","year":"2015","unstructured":"Reed, N. I. et al. The \u03b1v\u03b21 integrin plays a critical in vivo role in tissue fibrosis. Sci. Transl. Med. 7, 288ra79 (2015).","journal-title":"Sci. Transl. Med."},{"key":"1032_CR94","first-page":"626","volume":"21","author":"A Mullard","year":"2022","unstructured":"Mullard, A. Pliant\u2019s integrin inhibitor boosted by phase II IPF data. Nat. Rev. Drug. Discov. 21, 626 (2022).","journal-title":"Nat. Rev. Drug. Discov."},{"key":"1032_CR95","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/jid.2012.438","volume":"133","author":"S Liu","year":"2013","unstructured":"Liu, S. & Leask, A. Integrin \u03b21 is required for dermal homeostasis. J. Invest. Dermatol. 133, 899\u2013906 (2013).","journal-title":"J. Invest. Dermatol."},{"key":"1032_CR96","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/labinvest.2012.147","volume":"93","author":"MM Riopel","year":"2013","unstructured":"Riopel, M. M., Li, J., Liu, S., Leask, A. & Wang, R. \u03b21 integrin-extracellular matrix interactions are essential for maintaining exocrine pancreas architecture and function. Lab. Invest. 93, 31\u201340 (2013).","journal-title":"Lab. Invest."},{"key":"1032_CR97","doi-asserted-by":"publisher","first-page":"7799","DOI":"10.1167\/iovs.10-6945","volume":"52","author":"SK Parapuram","year":"2011","unstructured":"Parapuram, S. K., Huh, K., Liu, S. & Leask, A. Integrin \u03b21 is necessary for the maintenance of corneal structural integrity. Invest. Ophthalmol. Vis. Sci. 52, 7799\u20137806 (2011).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"1032_CR98","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12079-012-0170-6","volume":"6","author":"S Liu","year":"2012","unstructured":"Liu, S. & Leask, A. Integrin \u03b21 is required for maintenance of vascular tone in postnatal mice. J. Cell Commun. Signal. 6, 175\u2013180 (2012).","journal-title":"J. Cell Commun. Signal."},{"key":"1032_CR99","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s12079-022-00673-3","volume":"16","author":"C Zeltz","year":"2022","unstructured":"Zeltz, C. et al. Integrin \u03b111\u03b21 in tumor fibrosis: more than just another cancer-associated fibroblast biomarker? J. Cell Commun. Signal. 16, 649\u2013666 (2022).","journal-title":"J. Cell Commun. Signal."},{"key":"1032_CR100","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3390\/cancers11060765","volume":"11","author":"C Zeltz","year":"2019","unstructured":"Zeltz, C. et al. \u03b111\u03b21 integrin is induced in a subset of cancer-associated fibroblasts in desmoplastic tumor stroma and mediates in vitro cell migration. Cancers 11, 765 (2019).","journal-title":"Cancers"},{"key":"1032_CR101","doi-asserted-by":"publisher","first-page":"734749","DOI":"10.3389\/fcell.2021.734749","volume":"9","author":"W Wang","year":"2021","unstructured":"Wang, W. et al. TAK1: a molecular link between liver inflammation, fibrosis, steatosis, and carcinogenesis. Front. Cell Dev. Biol. 9, 734749 (2021).","journal-title":"Front. Cell Dev. Biol."},{"key":"1032_CR102","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/j.chembiol.2017.07.011","volume":"24","author":"J Totzke","year":"2017","unstructured":"Totzke, J. et al. Takinib, a selective TAK1 inhibitor, broadens the therapeutic efficacy of TNF-\u03b1 inhibition for cancer and autoimmune disease. Cell Chem. Biol. 24, 1029\u20131039.e7 (2017).","journal-title":"Cell Chem. Biol."},{"key":"1032_CR103","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1021\/acschembio.1c00788","volume":"17","author":"S Scarneo","year":"2022","unstructured":"Scarneo, S. et al. Development and efficacy of an orally bioavailable selective TAK1 inhibitor for the treatment of inflammatory arthritis. ACS Chem. Biol. 17, 536\u2013544 (2022).","journal-title":"ACS Chem. Biol."},{"key":"1032_CR104","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s13075-019-2073-x","volume":"21","author":"SA Scarneo","year":"2019","unstructured":"Scarneo, S. A. et al. Pharmacological inhibition of TAK1, with the selective inhibitor takinib, alleviates clinical manifestation of arthritis in CIA mice. Arthritis Res. Ther. 21, 292 (2019).","journal-title":"Arthritis Res. Ther."},{"key":"1032_CR105","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1101\/gad.304501.117","volume":"31","author":"CT Foster","year":"2017","unstructured":"Foster, C. T., Gualdrini, F. & Treisman, R. Mutual dependence of the MRTF-SRF and YAP-TEAD pathways in cancer-associated fibroblasts is indirect and mediated by cytoskeletal dynamics. Genes. Dev. 31, 2361\u20132375 (2017).","journal-title":"Genes. Dev."},{"key":"1032_CR106","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.2174\/0929867323666160316125048","volume":"23","author":"F Gibault","year":"2016","unstructured":"Gibault, F. et al. Non-photoinduced biological properties of verteporfin. Curr. Med. Chem. 23, 1171\u20131184 (2016).","journal-title":"Curr. Med. Chem."},{"key":"1032_CR107","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.3390\/cancers14092282","volume":"14","author":"L Seeneevassen","year":"2022","unstructured":"Seeneevassen, L., Dubus, P., Gronnier, C. & Varon, C. Hippo in gastric cancer: from signalling to therapy. Cancers 14, 2282 (2022).","journal-title":"Cancers"},{"key":"1032_CR108","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12079-020-00596-x","volume":"15","author":"X Shi-Wen","year":"2021","unstructured":"Shi-Wen, X. et al. Verteporfin inhibits the persistent fibrotic phenotype of lesional scleroderma dermal fibroblasts. J. Cell Commun. Signal. 15, 71\u201380 (2021).","journal-title":"J. Cell Commun. Signal."},{"key":"1032_CR109","first-page":"1191","volume":"82","author":"P Chitturi","year":"2023","unstructured":"Chitturi, P. et al. The Tripterygium wilfordii derivative celastrol, a YAP inhibitor, has anti-fibrotic effects in systemic sclerosis. Ann. Rheum. Dis. 82, 1191\u20131204 (2023).","journal-title":"Ann. Rheum. Dis."},{"key":"1032_CR110","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0126015","volume":"10","author":"X Shiwen","year":"2015","unstructured":"Shiwen, X. et al. A role of myocardin related transcription factor-A (MRTF-A) in scleroderma related fibrosis. PLoS ONE 10, e0126015 (2015).","journal-title":"PLoS ONE"},{"key":"1032_CR111","doi-asserted-by":"publisher","first-page":"2200604","DOI":"10.1183\/13993003.00604-2022","volume":"61","author":"HY Ma","year":"2023","unstructured":"Ma, H. Y. et al. Inhibition of MRTF activation as a clinically achievable anti-fibrotic mechanism for pirfenidone. Eur. Respir. J. 61, 2200604 (2023).","journal-title":"Eur. Respir. J."},{"key":"1032_CR112","doi-asserted-by":"publisher","first-page":"C1046","DOI":"10.1152\/ajpcell.00028.2020","volume":"318","author":"A Leask","year":"2020","unstructured":"Leask, A. Conjunction junction, what\u2019s the function? CCN proteins as targets in fibrosis and cancers. Am. J. Physiol. Cell Physiol. 318, C1046\u2013C1054 (2020).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"1032_CR113","doi-asserted-by":"publisher","first-page":"5635","DOI":"10.1091\/mbc.e04-06-0490","volume":"15","author":"Y Chen","year":"2004","unstructured":"Chen, Y. et al. CCN2 (connective tissue growth factor) promotes fibroblast adhesion to fibronectin. Mol. Biol. Cell 15, 5635\u20135646 (2004).","journal-title":"Mol. Biol. Cell"},{"key":"1032_CR114","doi-asserted-by":"publisher","first-page":"10715","DOI":"10.1074\/jbc.M511343200","volume":"281","author":"X Shi-wen","year":"2006","unstructured":"Shi-wen, X. et al. CCN2 is necessary for adhesive responses to transforming growth factor-\u03b21 in embryonic fibroblasts. J. Biol. Chem. 281, 10715\u201310726 (2006).","journal-title":"J. Biol. Chem."},{"key":"1032_CR115","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s12079-016-0324-z","volume":"10","author":"LF Lau","year":"2016","unstructured":"Lau, L. F. Cell surface receptors for CCN proteins. J. Cell Commun. Signal. 10, 121\u2013127 (2016).","journal-title":"J. Cell Commun. Signal."},{"key":"1032_CR116","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S2213-2600(19)30262-0","volume":"28","author":"L Richeldi","year":"2020","unstructured":"Richeldi, L. et al. Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir. Med. 28, 25\u201333 (2020).","journal-title":"Lancet Respir. Med."},{"key":"1032_CR117","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13075-017-1356-3","volume":"19","author":"K Makino","year":"2017","unstructured":"Makino, K. et al. Anti-connective tissue growth factor (CTGF\/CCN2) monoclonal antibody attenuates skin fibrosis in mice models of systemic sclerosis. Arthritis Res. Ther. 19, 134 (2017).","journal-title":"Arthritis Res. Ther."},{"key":"1032_CR118","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/wrr.12131","volume":"22","author":"S Liu","year":"2014","unstructured":"Liu, S., Thompson, K. & Leask, A. CCN2 expression by fibroblasts is not required for cutaneous tissue repair. Wound Repair. Regen. 22, 119\u2013124 (2014).","journal-title":"Wound Repair. Regen."},{"key":"1032_CR119","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1002\/art.38121","volume":"65","author":"S Liu","year":"2013","unstructured":"Liu, S., Parapuram, S. K. & Leask, A. Fibrosis caused by loss of PTEN expression in mouse fibroblasts is crucially dependent on CCN2. Arthritis Rheum. 65, 2940\u20132944 (2013).","journal-title":"Arthritis Rheum."},{"key":"1032_CR120","unstructured":"FibroGen. FibroGen announces topline results from phase 3 ZEPHYRUS-1 study of pamrevlumab for the treatment of idiopathic pulmonary fibrosis. FibroGen https:\/\/fibrogen.gcs-web.com\/news-releases\/news-release-details\/fibrogen-announces-topline-results-phase-3-zephyrus-1-study (2023)."},{"key":"1032_CR121","doi-asserted-by":"publisher","first-page":"L759","DOI":"10.1152\/ajplung.00190.2014","volume":"308","author":"S Grazioli","year":"2015","unstructured":"Grazioli, S. et al. CYR61 (CCN1) overexpression induces lung injury in mice. Am. J. Physiol. Lung Cell Mol. Physiol. 308, L759\u2013L765 (2015).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"1032_CR122","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1096\/fj.201500173","volume":"30","author":"AR Kurundkar","year":"2016","unstructured":"Kurundkar, A. R. et al. The matricellular protein CCN1 enhances TGF-\u03b21\/SMAD3-dependent profibrotic signaling in fibroblasts and contributes to fibrogenic responses to lung injury. FASEB J. 30, 2135\u20132150 (2016).","journal-title":"FASEB J."},{"key":"1032_CR123","doi-asserted-by":"publisher","first-page":"105821","DOI":"10.1016\/j.rmed.2019.105821","volume":"161","author":"T Kulkarni","year":"2020","unstructured":"Kulkarni, T. et al. The senescence-associated matricellular protein CCN1 in plasma of human subjects with idiopathic pulmonary fibrosis. Respir. Med. 161, 105821 (2020).","journal-title":"Respir. Med."},{"key":"1032_CR124","doi-asserted-by":"publisher","first-page":"100009","DOI":"10.1016\/j.mbplus.2019.100009","volume":"3","author":"K Quesnel","year":"2019","unstructured":"Quesnel, K. et al. CCN1 expression by fibroblasts is required for bleomycin-induced skin fibrosis. Matrix Biol. 3, 100009 (2019).","journal-title":"Matrix Biol."},{"key":"1032_CR125","first-page":"772","volume":"119","author":"M K\u00f6nigshoff","year":"2009","unstructured":"K\u00f6nigshoff, M. et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J. Clin. Invest. 119, 772\u2013787 (2009).","journal-title":"J. Clin. Invest."},{"key":"1032_CR126","unstructured":"FibroGen. Pamrevlumab trials. FibroGen https:\/\/www.fibrogen.com\/pamrevlumab-trials (2023)."},{"key":"1032_CR127","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19498-y","volume":"211","author":"G Lu","year":"2020","unstructured":"Lu, G. et al. Co-administered antibody improves penetration of antibody\u2013dye conjugate into human cancers with implications for antibody\u2013drug conjugates. Nat. Commun. 211, 5667 (2020).","journal-title":"Nat. Commun."},{"key":"1032_CR128","doi-asserted-by":"publisher","first-page":"952","DOI":"10.3390\/cells9040952","volume":"9","author":"A Resovi","year":"2020","unstructured":"Resovi, A. et al. CCN-based therapeutic peptides modify pancreatic ductal adenocarcinoma microenvironment and decrease tumor growth in combination with chemotherapy. Cells 9, 952 (2020).","journal-title":"Cells"},{"key":"1032_CR129","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s12079-015-0309-3","volume":"9","author":"BL Riser","year":"2015","unstructured":"Riser, B. L., Barnes, J. L. & Varani, J. Balanced regulation of the CCN family of matricellular proteins: a novel approach to the prevention and treatment of fibrosis and cancer. J. Cell Commun. Signal. 9, 327\u2013339 (2015).","journal-title":"J. Cell Commun. Signal."},{"key":"1032_CR130","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12079-015-0281-y","volume":"9","author":"A Leask","year":"2015","unstructured":"Leask, A. Yin and Yang revisited: CCN3 as an anti-fibrotic therapeutic? J. Cell Commun. Signal. 9, 97\u201398 (2015).","journal-title":"J. Cell Commun. Signal."},{"key":"1032_CR131","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12079-009-0056-4","volume":"3","author":"A Leask","year":"2009","unstructured":"& Leask, A. Yin and Yang: CCN3 inhibits the pro-fibrotic effects of CCN2. J. Cell Commun. Signal. 3, 161\u2013162 (2009).","journal-title":"J. Cell Commun. Signal."},{"key":"1032_CR132","unstructured":"Pliant Therapeutics. World-class drug development capabilities. Pliant https:\/\/pliantrx.com\/pipeline\/ (2023)."},{"key":"1032_CR133","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1093\/rheumatology\/keab168","volume":"60","author":"E Adami","year":"2021","unstructured":"Adami, E. et al. IL11 is elevated in systemic sclerosis and IL11-dependent ERK signalling underlies TGF\u03b2-mediated activation of dermal fibroblasts. Rheumatology 60, 5820\u20135826 (2021).","journal-title":"Rheumatology"},{"key":"1032_CR134","doi-asserted-by":"publisher","first-page":"9796","DOI":"10.3390\/ijms24129796","volume":"24","author":"G Werner","year":"2023","unstructured":"Werner, G. et al. Single-cell transcriptome analysis identifies subclusters with inflammatory fibroblast responses in localized scleroderma. Int. J. Mol. Sci. 24, 9796 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1032_CR135","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.3390\/ijms24043149","volume":"24","author":"Y Ishida","year":"2023","unstructured":"Ishida, Y., Kuninaka, Y., Mukaida, N. & Kondo, T. Immune mechanisms of pulmonary fibrosis with bleomycin. Int. J. Mol. Sci. 24, 3149 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"1032_CR136","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/978-1-0716-1382-5_20","volume":"2299","author":"D Lagares","year":"2021","unstructured":"Lagares, D. & Hinz, B. Animal and human models of tissue repair and fibrosis: an introduction. Methods Mol. Biol. 2299, 277\u2013290 (2021).","journal-title":"Methods Mol. Biol."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01032-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01032-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01032-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T09:04:45Z","timestamp":1698051885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-023-01032-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,3]]},"references-count":136,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["1032"],"URL":"https:\/\/doi.org\/10.1038\/s41584-023-01032-1","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,3]]},"assertion":[{"value":"31 August 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}